Q-omics provides the consensus-scored NMNAT1P3 profile across patient tissues and cancer cell-line models. NMNAT1P3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NMNAT1P3 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, NMNAT1P3 RNA expression shows 10,150 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, BRCA, and THYM as cancer lineages where NMNAT1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMNAT1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMNAT1P3 survival associations across molecular data types. NMNAT1P3 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMNAT1P3 RNA expression–survival associations across cancer types. High NMNAT1P3 expression shows unfavorable associations in MESO, LIHC, OV, PAAD and KIRC, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for NMNAT1P3 RNA expression.
This table summarizes NMNAT1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NMNAT1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMNAT1P3 shows lower tumor expression in BRCA, KICH and LUAD and higher tumor expression in KIRC and HNSC. The BRCA box plot shows higher NMNAT1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.069, t-test p < 0.001).
This table shows molecular features associated with NMNAT1P3 in patient tissues and cancer cell lines. In patient samples, NMNAT1P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
